GAMMA Investing LLC Sells 23 Shares of argenex SE (NASDAQ:ARGX)

GAMMA Investing LLC cut its holdings in argenex SE (NASDAQ:ARGX) by 9.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 229 shares of the company’s stock after selling 23 shares during the period. GAMMA Investing LLC’s holdings in argenex were worth $136,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. FMR LLC boosted its holdings in argenex by 17.2% in the fourth quarter. FMR LLC now owns 5,618,222 shares of the company’s stock worth $3,455,207,000 after purchasing an additional 824,750 shares in the last quarter. Capital World Investors boosted its holdings in argenex by 5.1% in the fourth quarter. Capital World Investors now owns 1,786,936 shares of the company’s stock worth $1,099,002,000 after purchasing an additional 86,687 shares in the last quarter. RTW Investments LP boosted its holdings in argenex by 2.9% in the fourth quarter. RTW Investments LP now owns 673,497 shares of the company’s stock worth $414,201,000 after purchasing an additional 19,067 shares in the last quarter. Clearbridge Investments LLC boosted its holdings in argenex by 6.8% in the fourth quarter. Clearbridge Investments LLC now owns 629,828 shares of the company’s stock worth $387,344,000 after purchasing an additional 40,330 shares in the last quarter. Finally, Lord Abbett & CO. LLC boosted its holdings in argenex by 26.5% in the fourth quarter. Lord Abbett & CO. LLC now owns 206,202 shares of the company’s stock worth $126,814,000 after purchasing an additional 43,239 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors.

argenex Stock Down 0.3%

NASDAQ ARGX opened at $543.32 on Friday. The company has a market capitalization of $33.18 billion, a P/E ratio of 33.52, a P/E/G ratio of 0.98 and a beta of 0.37. argenex SE has a 12-month low of $432.96 and a 12-month high of $678.21. The firm has a 50-day moving average price of $575.98 and a two-hundred day moving average price of $604.43.

argenex (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, May 8th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.32 by $0.26. The firm had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $748.34 million. argenex had a net margin of 40.20% and a return on equity of 16.15%. Equities analysts expect that argenex SE will post 3.13 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Citigroup reiterated a “buy” rating on shares of argenex in a report on Wednesday, May 21st. Sanford C. Bernstein upgraded shares of argenex from a “market perform” rating to an “outperform” rating in a report on Monday, March 17th. JMP Securities set a $699.00 price target on shares of argenex in a report on Wednesday, May 14th. HC Wainwright restated a “buy” rating and set a $720.00 price target on shares of argenex in a report on Tuesday, July 1st. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of argenex from a “sell” rating to a “hold” rating in a report on Wednesday, March 12th. One investment analyst has rated the stock with a hold rating, eighteen have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $728.06.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.